NovaSignal develops the FDA-cleared NovaGuide Intelligent Ultrasound, which combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time. The company leverages cloud computing and data analytics to support physicians' clinical decision making across neurological conditions including stroke, traumatic brain injury, and dementia. In April it launched a fully autonomous, cloud-connected NovaSignal Platform intended to simplify and broaden cerebral assessments in stroke programs. NovaSignal has broadened its commercial footprint beyond the U.S. and Europe after securing Health Canada license approval. The company raised $37M in a Series C1 to support continued commercial expansion, product innovation, and new clinical trials to increase indications within and beyond stroke. Leadership includes Chair and CEO Diane Bryant and co-founder and Chief Scientific Officer Robert Hamilton. Neural Analytics develops and commercializes medical robotics and machine‑learning technologies to measure and track brain health. Its core product is the Lucid Robotic System, which combines the Lucid M1 Transcranial Doppler (TCD) System with the NeuralBot system to perform autonomous neurovascular ultrasound and display brain blood flow information in real time. The Lucid Robotic System is designed for use across the patient care chain, including bubble studies to identify right‑to‑left shunts, cerebral blood flow velocity monitoring, and emboli monitoring, and is active at select centers around the United States. The company integrates ultrasound, robotics and machine learning and secured U.S. FDA clearance and a European CE mark in 2018. Neural Analytics recently enrolled its first patients into the CODEX Study, a prospective, single‑arm, global multi‑center study using an investigational iteration of the Lucid Robotic System. The company raised approximately $22 million in a Series C financing and issued warrants in connection with the raise; total funding for the company is approximately $66 million. With the new financing Neural Analytics plans to launch the Lucid Robotic System into clinical environments and continue expanding commercialization. Neural Analytics produces the Lucid Transcranial Doppler Ultrasound System, a portable, battery-operated tablet device that noninvasively assesses cerebral blood flow velocities at the point of care. The Lucid System is FDA-cleared and CE-marked and is designed for rapid assessment in clinical and medical-responder scenarios. The company focuses on acute ischemic stroke, traumatic brain injury, and dementia and combines data science with hardware to deliver objective physiological measurements. Neural Analytics intends to expand its team and further advance the Lucid System to assess and monitor additional brain health conditions. In an IRB-approved first phase of the EXPEDITE program, the Lucid System demonstrated 91% sensitivity and 85% specificity for detecting large vessel occlusion versus standard imaging. The company was founded in 2013 and is based in Los Angeles. Neural Analytics combines data science with hardware to create products and services that measure, diagnose and track brain health. Its flagship product, the Lucid M1 Transcranial Doppler Ultrasound System, is an all-in-one ultrasound system designed to measure and display cerebral blood flow velocities and monitor patients with brain disorders. The Lucid System has received FDA clearance and CE Mark approval and is currently available in the U.S. and Europe. The company emphasizes portability, autonomy, reliability, and precise objective physiological measurements for first responders and clinicians. Neural Analytics is conducting a feasibility study with Erlanger Health System in Chattanooga, Tennessee, to evaluate the Lucid System for patients suffering an acute ischemic stroke. The company plans to use funding to expand commercialization in the U.S. and Europe and to continue research toward earlier diagnosis of brain health conditions. Neural Analytics develops portable medical devices and services to measure, diagnose and track brain health, with a current focus on traumatic brain injury (TBI). The company combines data science with medical robotics to enable first responders and clinicians to assess mild to severe TBI, including concussions. Its devices are described as portable, reliable and producing precise, objective physiological measurements. Neural Analytics announced a $10 million Series A to fund clinical trials and product development. The company plans to use the funds to support clinical trials in 2016 and ongoing development of new products and research studies on TBI, including among athletes in high‑risk sports. The company reported total investment of $13 million to date, including a $3 million Series Seed last year.

Total raised

$94M

Funding rounds

5

Latest round

Series C

Latest activity

Sep 2021